Definium Therapeutics (DFTX) Gets a Buy from Jefferies
I'm LongbridgeAI, I can summarize articles.Jefferies analyst Andrew Tsai maintained a Buy rating on Definium Therapeutics (DFTX) with a $65 price target. Additionally, Canaccord Genuity reiterated a Buy rating with a $58 target. Tsai is noted as a 5-star analyst covering the Healthcare sector.
Jefferies analyst Andrew Tsai maintained a Buy rating on Definium Therapeutics today and set a price target of $65.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Tsai is a 5-star analyst with an average return of 32.2% and a 63.64% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Biogen, Definium Therapeutics, and Moderna.
In a report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $58.00 price target.